ストックスクリーナーアプリを入手
19.93
0.61%
0.115
Dyne Therapeutics Inc (DYN) 最新ニュース
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline? - Yahoo Finance
Potential Leadership Change at FDA Could Affect Dyne Therapeutics (DYN) - GuruFocus
Portfolio Shifts: Is Dyne Therapeutics Inc being accumulated by smart money2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Breakouts Watch: Will Dyne Therapeutics Inc benefit from government policy2026 Review & Growth Focused Stock Reports - baoquankhu1.vn
Chipmakers Recap: Is Dyne Therapeutics Inc gaining market share2026 Price Targets & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Travel Stocks: Is now the right time to enter Dyne Therapeutics IncIPO Watch & Safe Capital Growth Plans - baoquankhu1.vn
Dyne Therapeutics (NASDAQ: DYN) asks shareholders to approve 400M-cap increase - Stock Titan
Fundamentals Check: Is Dyne Therapeutics Inc gaining market share2026 Dividend Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Precision Trading with Dyne Therapeutics Inc. (DYN) Risk Zones - Stock Traders Daily
Signal Recap: Is Dyne Therapeutics Inc gaining market shareGap Down & Daily Volume Surge Signals - baoquankhu1.vn
DYN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Dyne Therapeutics Inc benefit from green energy policiesMarket Activity Recap & Fast Gain Stock Tips - baoquankhu1.vn
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - Stock Titan
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Bullish analyst opinion on Dyne (DYNE) follows rare disease drug progress in Japan - MSN
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co. - MarketBeat
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% HigherHere's Why - MarketBeat
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference - MarketBeat
Published on: 2026-03-19 20:58:12 - baoquankhu1.vn
Dyne Therapeutics details complex risk patterns and urgent care need for DM1 patients - Traders Union
Retail Trends: Is now the right time to enter Dyne Therapeutics IncOil Prices & Comprehensive Market Scan Insights - baoquankhu1.vn
Earnings Beat: Will Dyne Therapeutics Inc benefit from government policyWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Trading the Move, Not the Narrative: (DYN) Edition - Stock Traders Daily
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)? - simplywall.st
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
2.43%
0.01%
大文字化:
|
ボリューム (24 時間):